Join our Provider Relations team members for the virtual provider collaboration session(s). Register Now
Register for the upcoming 2027 Change Provider Trainings
Join our Provider Relations team members for the virtual provider collaboration session(s). Register Now
Blue Cross Blue Shield of North Dakota (BCBSND) continually develops and revises pharmacy policies in response to rapidly changing pharmaceutical requirements. Our commitment is to update the provider community as pharmacy policies are adopted and/or revised.
Commercial Updates for Non-migrated Members - Medical Pharmacy
The following Commercial prior authorization medical drug policies are new and effective Jan. 1, 2027:
The following Commercial prior authorization medical drug policies will be archived effective Dec. 7, 2026:
Retail Pharmacy
The following retail pharmacy Utilization Management (UM) programs have updates effective Jan. 1, 2027:
UM Program Name | Program Type | Formulary | Update for Provider Letter |
Agamree and Emflaza | PAQL | Commercial, HIM, NetResults | *standardized wording and format of language *clinical criteria update |
Androgens and Anabolic Steroids | PAQL | Commercial, HIM, NetResults | *clinical criteria update |
Anti-Covid19 | QL | Commercial, HIM, NetResults | *adding Xocova and clinical criteria update |
Antifungals | PAQL | Commercial, HIM, NetResults | *clinical criteria and quantity limit update on Brexafemme |
Antiretroviral | QL | NetResults | *adding Bixlenvo and Bixlenvo/Sunlenca starter pack and clinical criteria update |
Anzupgo | PAQL | Commercial, HIM, NetResults | *clinical criteria update |
ApoC3 targeting Agents | PAQL | Commercial, HIM, NetResults | *Program name change from Familial Chylomicronemia Syndrome (FCS) to "ApoC3 Targeting Agents *clinical criteria update |
APRIL Inhibitors (formerly Voyxact) | PAQL | Commercial, HIM | *Program renamed to "APRIL Inhibitors" to accommodate addition of new target Trutakna *adding Trutakna and clinical criteria update |
Atypical Antipsychotic ER | PA | Commercial | *adding Weltruza and clinical criteria update |
Bempedoic Acid | PAQL | Commercial, HIM, NetResults | *clinical criteria update |
Biologic Immunomodulators (OP) | PAQL | NetResults | *clinical criteria update |
Carbaglu | PA | Commercial, HIM, NetResults | *clinical criteria update |
Cardiac Myosin Inhibitors | PAQL | Commercial, HIM, NetResults | *clinical criteria update |
Copay Waiver ACA Prevention | CE | Commercial, HIM, NetResults | *clinical criteria update |
Corticotropin | PA | Commercial, HIM, NetResults | *no changes on annual review |
Coverage Exception | CE | HIM | *no changes on annual review |
Coverage Exception | CE | NetResults | *no changes on annual review |
Crenessity | PAQL | Commercial, HIM, NetResults | *clinical criteria update |
Dojolvi | PA | NetResults | *no changes on annual review |
DPP-4 inhibitors and combinations | PAQL | Commercial, HIM, NetResults | *adding sitagliptin ER to the preferred and moving brand Janumet XR to non-preferred |
Duvyzat | PAQL | Commercial, HIM, NetResults | *clinical criteria update *standardized wording and format of language |
Efgartigimod | PAQL | Commercial, HIM, NetResults | *clinical criteria update *initial approval length increased to 12 months |
Elagolix/Relugolix | PAQL | Commercial, HIM, NetResults | *clinical criteria update |
Empaveli (pegcetacoplan) | PAQL | Commercial, HIM, NetResults | *clinical criteria update *initial approval length increased to 12 months *renewal criteria update *standardized wording and format of language |
Enspryng (satralizumab-mwge) | PAQL | Commercial, HIM, NetResults | *clinical criteria update |
Fabhalta (iptacopan) | PAQL | Commercial, HIM, NetResults | *clinical criteria update and initial approval length increased to 12 months *renewal criteria update |
Filspari (sparsentan) | PAQL | Commercial, HIM, NetResults | *clinical criteria update *renewal criteria update |
Filsuvez | PA | NetResults | *clinical criteria update and initial approval length increased to 12 months |
Fintepla | PAQL | NetResults | *clinical criteria update |
GLP-1 Agonists | PAQL | Commercial, HIM, NetResults | *clinical criteria updates *Removed Mounjaro 2.5mg quantity limit language regarding maintenance dosing |
Growth Hormone | PA | Commercial, HIM, NetResults | *removed Saizen (obsolete) *clinical criteria update and standardized wording and format of language *renewal criteria update |
Hyftor | PAQL | NetResults | *initial approval length increased to 12 months |
Hympavzi | PAQL | Commercial, HIM, NetResults | *clinical criteria and quantity limit criteria updates |
IL-13 Inhibitors | PAQL | Commercial, HIM, NetResults | *clinical criteria update *renewal criteria update |
IL-4 Inhibitors | PAQL | Commercial, HIM, NetResults | *clinical criteria update |
Isturisa | PAQL | Commercial, HIM, NetResults | *initial approval length increased to 12 months |
Joenja | PAQL | NetResults | *standardized wording and format of language *clinical criteria update |
Journavyx | PA | NetResults | *clinical criteria and quantity limit updates |
Korlym | PAQL | Commercial, HIM, NetResults | *clinical criteria update and initial approval length increased to 12 months |
Leqembi | PAQL | Commercial, HIM, NetResults | *clinical criteria update *renewal criteria update *standardized wording and format of language |
Long Acting Insulin PA | PA | Commercial, HIM, NetResults | *adding Awigli flex and Langlara and clinical criteria update |
Myalept | PA | Commercial, HIM, NetResults | *no changes on annual review |
Opzelura | PAQL | NetResults | *clinical criteria update and initial approval length increased to 12 months |
Parathyroid Hormone Analog Osteoporosis | PAQL | Commercial, HIM, NetResults | *no changes on annual review |
PCSK9 PAQL | PAQL | Commercial, HIM, NetResults | *adding Lipfendra and clinical criteria update |
Phenylketonuria | PA | Commercial, HIM, NetResults | *clinical criteria update and initial approval length increased to 12 months *standardized wording and format of language |
Procysbi (cysteamine bitartrate) | PA | Commercial, HIM, NetResults | *clinical criteria update *standardized wording and format of language |
Progesterones | STQL | NetResults | *clinical criteria update |
Pulmonary Arterial Hypertension (PAH) | PAQL | Commercial, HIM, NetResults | *clinical criteria update |
Rare Neurogenetic Disease Agents | PAQL | Commercial, HIM, NetResults | *clinical criteria update and initial approval length increased to 12 months *program name update *renewal criteria update |
Recorlev (levoketoconazole) | PAQL | Commercial, HIM, NetResults | *initial approval length increased to 12 months |
Retinoids (topical) | PA | Commercial, HIM, NetResults | *clinical criteria update |
SA Oncology | PAQL | Commercial, HIM, NetResults | *adding Zegfrovy, Zenbexus, Jideytro, Ectamah, Mimlyro Rasonque and Beqalzi and clinical criteria update *removed Tazverik, Kisqali-Femara co-pack, retevmo capsules and Thalomid 150mg and 200mg (obsolete) |
Sensipar | PA | Commercial, HIM, NetResults | *no changes on annual review |
Sohonos | PAQL | Commercial, HIM, NetResults | *no changes on annual review |
Strensiq | PA | Commercial, HIM, NetResults | *initial approval length increased to 12 months |
Substrate Reduction Therapy | PAQL | Commercial, HIM, NetResults | *clinical criteria update *standardized wording and format of language |
Sucraid (sacrosidase) | PAQL | NetResults | *clinical criteria update and initial approval length increased to 12 months *standardized wording and format of language *clinical criteria and quantity limit criteria updates *Quantity limit update |
Topical AK, BCC, EGW Agents | PAQL | NetResults | *program name update *clinical criteria update *initial approval length increased to 6 months * Removed Aldara 5% cream (obsolete) |
Topical Antifungals, itraconazole, terbinafine | PAQL | NetResults | *clinical criteria and quantity limit updates on Sporanox oral solution *initial approval length increased to 6 months (oropharyngeal/esophageal candidiasis) |
Topical Corticosteroids | QL | Commercial, HIM, NetResults | *removed the following obsolete drugs: flucinolone shampoo 0.001%, amcinonide lotion 0.1& and hydrocortisone lipo base cream 0.1& |
Topical crisaborole, pimecrolimus, tacrolimus (previously Atopic Dermatitis) | ST | Commercial, HIM, NetResults | *program name update |
Topical Doxepin | PAQL | NetResults | *clinical criteria update |
Topical Estrogen | QL | NetResults | *standardized wording and format of language |
Topical Lidocaine | PAQL | NetResults | *no changes on annual review |
Topical NSAID | STQL | Commercial, HIM, NetResults | *clinical criteria update (step to apply patients 18 years and older and QL to apply to all ages) |
Triptan | STQL | Commercial, HIM, NetResults | *adding Rizafilm and clinical criteria update |
Urea Cycle Disorders | PA | NetResults | *clinical criteria update *standardized wording and format of language |
Voxzogo | PAQL | NetResults | *no changes on annual review |
Vyjuvek | PAQL | Commercial, HIM, NetResults | *clinical criteria update |
Weight Management | PAQL | Commercial, HIM, NetResults | *clinical criteria update *renewal criteria update |
Xdemvy (lotilaner) | PAQL | NetResults | *program name update |
Xolair PA | PQ | Commercial, HIM, NetResults | *adding Omlyclo and clinical criteria update |
Yorvipath | PAQL | Commercial, HIM, NetResults | *initial approval length increased to 12 months |
Zelsuvm | PAQL | Commercial, HIM, NetResults | *no changes on annual review |
Zeposia | PAQL | Commercial, HIM, NetResults | *clinical criteria update |
The following retail pharmacy Utilization Management (UM) programs will be archived effective Jan. 1, 2027:
Commercial Updates for Non-migrated and Migrated Members - Medical Pharmacy
The following Commercial prior authorization medical drug policies will be archived effective Jan. 1, 2027, for migrated and non-migrated members:
The following Commercial prior authorization medical drug policies will have preferred products changes Jan. 1, 2027, for migrated and non-migrated members:
The following Commercial medical drugs that currently have post service claim edit (PSCE) will no longer have PSCE effective Jan. 1, 2027, for migrated and non-migrated members:
Commercial Updates for Migrated Members - Medical Pharmacy
The following Commercial prior authorization medical drug policies are new and effective Jan. 1, 2027, for migrated members:
The following new to market drugs will have Commercial prior authorization medical drug policies adopted for migrated members:
The following Commercial prior authorization medical drug policies have criteria updates effective Jan. 1, 2027, for migrated members:
The following Commercial medical drugs will no longer have coverage effective Jan. 1, 2027, for migrated members:
PSCEs will apply to the following clinician-administered drugs billed under the medical drug benefit for eligible migrated members effective Jan.1, 2027:
Retail Pharmacy
The following retail pharmacy Utilization Management (UM) programs are new and effective Jan. 1, 2027, for migrated members:
The following retail pharmacy Utilization Management (UM) programs will be archived effective Jan. 1, 2027, for migrated members:
The following retail pharmacy Utilization Management (UM) programs have updates effective Jan. 1, 2027, for migrated members: